NBCC’s advocacy has resulted in more than $4 billion federal dollars for breast cancer research.
NBCC has engaged as a key partner in seminal clinical trials, including the pivotal trial of trastuzumab (Herceptin)
Since 1995 NBCC has trained over 2,400 Project LEAD graduates in research and advocacy.
Through the Artemis Project®, NBCC developed a preventive vaccine that is now moving into a Phase I clinical trial.
